InsidersTradesSigma
Follow the BioCardia, Inc. stock price and the full management transaction log of the company, a listed issuer based in United States. Shares are quoted on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, BioCardia, Inc. has published 129 public disclosures. Market capitalisation: €17.3m. The latest transaction was reported on 4 September 2026 (Acquisition). Among the most active insiders: Altman Peter. Every trade is free.
129
Insider Decl.
n/a
Thresholds
€3m
81 ops.
Buy Volume
€57,589
2 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate BioCardia, Inc. Strong Buy (bullish), based on 2 analysts. Average price target: US$15.50.
44Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 4 September 2026
Declarations129 total
800 shares@ US$1.090.0051% mcap0.1% of flowCommon StockSEC:0001437749-26-029732:0
Canonical exit: 2 Dec 2026 (T+90)
5,400 shares@ US$0.930.036% mcap0.4% of flowCommon StockSEC:0001437749-26-028307:0
Canonical exit: 15 Nov 2026 (T+90)
1,900 shares@ US$0.920.013% mcap0.1% of flowCommon StockSEC:0001437749-26-027743:0
Canonical exit: 11 Nov 2026 (T+90)
5,000 shares@ US$0.780.033% mcap0.3% of flowCommon StockSEC:0001437749-26-024925:0
Canonical exit: 27 Oct 2026 (T+90)
500 shares@ US$0.830.0034% mcap0.0% of flowCommon StockSEC:0001437749-26-023868:0
Canonical exit: 15 Oct 2026 (T+90)
2,800 shares@ US$0.880.021% mcap0.2% of flowCommon StockSEC:0001437749-26-023637:0
Canonical exit: 12 Oct 2026 (T+90)
1,500 shares@ US$0.860.011% mcap0.1% of flowCommon StockSEC:0001437749-26-023637:1
Canonical exit: 13 Oct 2026 (T+90)
1,000 shares@ US$0.900.0068% mcap0.1% of flowCommon StockSEC:0001437749-26-023365:1
Canonical exit: 7 Oct 2026 (T+90)
5,500 shares@ US$0.970.040% mcap0.4% of flowCommon StockSEC:0001437749-26-023365:0
Canonical exit: 6 Oct 2026 (T+90)
1,000 shares@ US$0.940.0071% mcap0.1% of flowCommon StockSEC:0001437749-26-023365:2
Canonical exit: 8 Oct 2026 (T+90)
5,400 shares@ US$0.96450.035% mcap0.5% of flowCommon StockSEC:0001437749-26-023016:0
Canonical exit: 6 Oct 2026 (T+90)
17,269 shares@ US$1.240.12% mcap7.8% of flowCommon StockSEC:0001437749-26-022967:0
23,125 shares@ US$1.240.16% mcap6.5% of flowCommon StockSEC:0001437749-26-022968:0
54,606 shares@ US$1.240.38% mcap6.0% of flowCommon StockSEC:0001437749-26-022969:0
110,625 sharesCommon StockSEC:0001437749-26-022365:0
39,521 sharesCommon StockSEC:0001437749-26-022363:0
60,483 sharesCommon StockSEC:0001437749-26-022364:0
70,200 sharesCommon StockSEC:0001437749-26-021597:0
Canonical exit: 20 Sept 2026 (T+90)
39,000 sharesCommon StockSEC:0001437749-26-021597:1
Canonical exit: 21 Sept 2026 (T+90)
1,500 sharesCommon StockSEC:0001437749-26-021216:0
Canonical exit: 15 Sept 2026 (T+90)
800 sharesCommon StockSEC:0001437749-26-021216:1
Canonical exit: 16 Sept 2026 (T+90)
5,000 sharesCommon StockSEC:0001437749-26-020044:0
Canonical exit: 7 Sept 2026 (T+90)
200 shares@ US$0.950.0015% mcap0.0% of flowCommon StockSEC:0001437749-26-018125:0
Canonical exit: 17 Aug 2026 (T+90)
1,500 shares@ US$0.920.011% mcap0.1% of flowCommon StockSEC:0001437749-26-018125:1
Canonical exit: 18 Aug 2026 (T+90)
5,100 shares@ US$1.020.040% mcap2.5% of flowCommon StockSEC:0001437749-26-017459:0
Canonical exit: 13 Aug 2026 (T+90)
25 of 129 declarations
关于 BioCardia, Inc.
BioCardia, Inc.（股票代码：BCDA）是一家在美国纳斯达克上市的美国生物技术公司，专注于细胞疗法及相关递送系统，用于治疗存在大量未满足医疗需求的心血管和肺部疾病。公司总部位于加利福尼亚州桑尼维尔，在一个业务部门运营，最适合被描述为临床阶段的再生医学平台，而非商业制药制造商。其战略核心是开发细胞和细胞衍生疗法，并结合专有的微创递送和导航技术，旨在将治疗直接送达目标组织。（[sec.gov](https://www.sec.gov/Archives/edgar/data/925741/000143774925009397/bcda20241231_10k.htm?utm_source=openai)) BioCardia 的历史植根于再生医学和心脏介入。随着时间的推移，公司围绕细胞治疗项目和导管递送工具建立了一个产品组合，随后在反向并购交易后采用了 BioCardia 的名称。公司业务高度集中在美国，核心业务位于桑尼维尔，并拥有一个精简的组织架构，包括临床开发、产品开发、监管、制造、质量、财务、行政和商业支持职能。（[sec.gov](https://www.sec.gov/Archives/edgar/data/925741/000143774925009397/bcda20241231_10k.htm?utm_source=openai)) 公司的核心产品线由 CardiAMP® 领先，这是一种用于射血分数降低的缺血性心力衰竭的自体单核细胞疗法。BioCardia 还开发 CardiALLO™，这是一种研究性同种异体“现成”细胞治疗平台，以及 Helix™ 生物治疗递送系统，这是一种经心内膜导管平台，用于将治疗或诊断剂递送至心脏。此外，公司的 Morph® DNA 可转向引入器产品支持手术过程中的导航和定位。这种集成产品堆栈是一个关键的差异化因素：BioCardia 不仅在开发一种疗法，还在开发实施该疗法所需的程序基础设施。（[biocardia.com](https://www.biocardia.com/about-us/about-biocardia/id/1008?utm_source=openai)) 从竞争角度来看，BioCardia 仍然是一家专业化的、处于开发阶段的公司，商业规模有限，高度依赖临床、监管和融资里程碑。其目标市场包括缺血性心力衰竭和难治性心绞痛，这些领域的治疗选择仍然受限。在 2025 年和 2026 年，公司强调了 CardiAMP HF 的后期数据以及与 FDA 和日本 PMDA 的持续讨论。2026 年 3 月，BioCardia 报告称 FDA 接受了其 Helix 预提交方案，2026 年 5 月，公司表示 FDA 已就该递送系统可能的批准途径达成一致，这可能会随着时间的推移提高监管可见度。（[globenewswire.com](https://www.globenewswire.com/en/news-release/2025/03/31/3052241/0/en/biocardia-phase-3-cardiamp-hf-trial-of-novel-cardiac-cell-therapy-for-ischemic-heart-failure-shows-increased-survival-decreased-cardiac-events-and-improved-quality-of-life-at-two-y.html?utm_source=openai)) 对于投资者而言，BioCardia 是一个高风险、高选择性的投资故事：一家拥有差异化技术、美国制造和开发基地、以及与试验结果、监管批准以及最终合作或商业化机会相关的巨大上行空间的微市值临床生物治疗公司。（[biocardia.com](https://www.biocardia.com/investors/press-releases/id/1037?pressReleaseId=256&utm_source=openai))
